ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Consumer Discretionary / OPRX
UXIN (30) DHX (54) CNDT (33) ALIT (31) ⌘ Pro Terminal β†’

OptimizeRx Corporation (OPRX) β€” RQD Stock Rating Cockpit

$9.32 -0.53% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.33

OptimizeRx Corporation (OPRX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (67% profit margin, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate) β†’
ROARABLE B- β€’ BUY Cap $176.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OPRX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is OPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $9.32 (-0.53% 1D, market cap $176.5M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1011 tracked Consumer Discretionary issuers, OPRX ranks #142 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does OPRX compare to UXIN and DHX in the Consumer Discretionary sector?
β–Ό

Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (71/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and DHX (DHI Group Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -7.4%, cap $210.2M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OPRX?
β–Ό

Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.33 (+0.14%)🧬 Cannibal Buyback (-2.08% YoY Shares)βš™οΈ Cash Engine: 14/20 (B-) β€’ 17% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510071
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ Β· Rk B
Cash (14)Whales (12)SEC (14)Macro (16)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
$22 Bull$10 Base$8 Bear
πŸ“¬ FREE OPRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for OPRX)Realized 20D OHLCV Swing Band: Β±10.3%
Deterministic 5-Pillar Attribution (71/100 Composite)
πŸ” WHY OPRX SCORES 71/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+16/20 pts (23% of score)

FRED Regime Γ— Technicals: 29% of 52W Range β€’ RSI-14 at 64.3 (BULLISH MOMENTUM)

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy β€’ Cannibal Buyback (-2.08% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
63
Grade C+$8.22+6.3% Next Q
Q2 (-2Q)
66
Grade B-$8.74+3.8% Next Q
Q3 (-1Q)
68
Grade B-$9.07+2.8% Next Q
Current
71
Grade B-$9.32+6.8% Hist 90D Ξ±
Trajectory: C+ (63) β†’ B- (71)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the OPRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 71/100 (B-) score, OPRX faces multiple-compression risk if 34.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) β€” any gross margin slip below 64.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($8.23) or 200D SMA ($7.28) invalidates the momentum regime and cuts Target Base ($9.87) toward Bear Floor ($7.64).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OPRXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œOPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 71%NO 29%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
64.330 Oversold Β· 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.68>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE29% OF RANGE
L: $5$9.32H: $21
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (67% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on OPRX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

7.3% ROIC with 67.3% gross margin and 10.57% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 2.68 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (72)

27/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like OPRX
  • βœ“Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (OPRX Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
OPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.67%β–² ASCENDING CHANNEL
2026-11-02O $9.30H $9.37L $9.30C $9.32VOL 100.5K
RES: $9.89SUP: $8.37SMA50: $8.23SMA200: $7.28
$13.69$11.21$8.73$6.25$3.77RES $9.89SUP $8.37$9.322026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ OPRX Butterfly Map β†’ + Track OPRX β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
26.5%/yr Implied 5Y Growth

vs. +18.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OPRX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for OPRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OPRX)

Consumer Discretionary Rank #142 of 1011 βš”οΈ UXIN vs OPRX Full Matrix β†’

1. Head-to-Head Consumer Discretionary Peer Comparison (OPRX vs. UXIN, DHX, CNDT, ALIT)

Industry: Business Services (90 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, OptimizeRx Corporation (OPRX) ranks #142 by composite RQD confidence (71/100, grade B-) and #708 by equity capitalization ($176.5M). Within this direct 5-issuer industry benchmark cohort, OPRX leads on earnings valuation at 34.4x trailing P/E, while OPRX leads on capital efficiency and profitability with 7.3% ROIC and 67.3% gross margin. OPRX currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OPRX ACTIVE
OptimizeRx Corporation
B- 71/100 34.4x 67.3% 7.3% -0.53% $176.5M Benchmark Subject
UXIN
Uxin Limited ADS
E 30/100 β€” 6.7% -35.0% -5.34% $206.8M /uxin-vs-oprx β†’
DHX
DHI Group Inc.
D+ 54/100 β€” 84.7% -7.4% -6.61% $210.2M /dhx-vs-oprx β†’
CNDT
Conduent Incorporated
E 33/100 β€” 18.1% -24.8% -0.64% $241.1M /cndt-vs-oprx β†’
ALIT
Alight Inc. (Class A)
E 31/100 β€” 33.8% -35.0% -2.62% $247.0M /alit-vs-oprx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001448431

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OptimizeRx Corporation (OPRX) reported GAAP revenue of $109.4M (+18.8% vs. FY2024 revenue of $92.1M , and +53.0% cumulative change since FY2023) , GAAP net income of $5.1M, operating cash flow of $18.7M, and free cash flow of $18.7M (+290.6% YoY). On the balance sheet, OPRX closed FY2025 with $176.9M in total assets against $21.4M in total debt (Altman Z-Score: 2.68, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $109.4M $5.1M $18.7M $18.7M $176.9M $21.4M
FY2024 (FY) 2024-12-31 $92.1M -$20.1M $4.9M $4.8M $171.2M $30.8M
FY2023 (FY) 2023-12-31 $71.5M -$17.6M -$7.2M -$7.2M β€” β€”

3. OPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $9.32 (-0.53% 1D, market cap $176.5M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1011 tracked Consumer Discretionary issuers, OPRX ranks #142 in composite RQD confidence.

How does OPRX compare to UXIN and DHX in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (71/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and DHX (DHI Group Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -7.4%, cap $210.2M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OPRX?

Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

OPRX last traded at $9.32 (-0.53% on volume of 136,559 shares), positioning the stock +13.24% above its 50-day simple moving average ($8.23) and +28.02% above its 200-day simple moving average ($7.28). Across its 52-week range of $4.54 to $21.09, OPRX sits at the 28.9% percentile with a 14-day RSI of 64.3 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.3% ($8.36 to $10.28).

OPRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell OPRX stock right now?

OptimizeRx Corporation (OPRX) currently earns a Roarable Rating of B- (Buy β€” BUY) with 71/100 RQD Confidence. High-quality cash engine (67% profit margin, 7% return on capital) with steady institutional support.

What is OPRX's 12-month price target and RQD AI Jury consensus?

OPRX's 12-month base price target is $9.87 (range $7.64 to $22.14), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OPRX RQD Cockpit OPRX 12M Forecast OPRX Earnings & Move OPRX Dividends & DRIP OPRX Insiders & 13F OPRX Whale Options OPRX Profit Sankey OPRX News & Why
ROARABLE RATING BRIEF β€’ RQD 71/100 (B-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

OPRX β€” OptimizeRx Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, OPRX scores 71 out of 100, graded B- and labeled "Roarable Buy β€” Sound Institutional Accumulation." The five pillars are:

  • Fundamental Cash Engine: 14 / 20. Per the RQD rating, this reflects ROIC of 7.3% and an FCF yield of 10.57%. For an investor, the FCF yield signals that the business generates meaningful cash relative to its market value, while the modest ROIC indicates capital is not yet compounding at a high rate.
  • Whale 13F Flow: 12 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. The score is the lowest of the five, so institutional support is present but not the strongest signal in the rating. Holder-level detail is not available in source data.
  • Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. Insider activity is a moderate positive; the underlying trade detail is not available in source data.
  • Macro Regime Fit: 16 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. This is the strongest pillar, suggesting market-level risk is roughly in line with the broader market.
  • Forensic Balance Sheet: 14 / 20. Per the RQD rating, Altman Z is 2.68, Piotroski F is 9/9, and Debt/Equity is 0.17. The strong Piotroski reading and low leverage are supportive; the Altman Z sits in a range that warrants monitoring rather than comfort.

Investor implications, framed analytically: upside drivers in the data include the high FCF yield, strong Piotroski reading, low leverage, and the recent turn to positive FY 2025 net income. The valuation tradeoff is visible in the multiples: P/E (TTM) of 34.4 and EV/EBITDA of 14.9 against an EPS (TTM) of 0.27 and a 52-week range of $4.54 to $21.09, which shows the stock has moved sharply in both directions over the past year. The price of 9.37 sits well below the 52-week high, which is a fact about price history and not a judgment on value.

Snapshot

Per the market data section:

MetricValue
Price9.37
Market Cap$176.5M
P/E (TTM)34.4
Forward P/E28.9
EV/EBITDA14.9
EPS (TTM)0.27
Dividend Yield0%
Beta1.0
52-Wk Range$4.54 - $21.09
ROIC %7.3%

Business

Sector is Consumer Discretionary and industry is Business Services, listed on NASDAQ, per the company profile. The profile section does not describe the company's products, customers, or revenue model. Per the market data section, gross margin is 67.3%, operating margin is 10.7%, and net margin is 4.7%. Specific details on what the company sells, to whom, and how it earns revenue are not available in source data.

Financial Trend

Per the SEC financials section:

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$109.4M$11.7M$5.1MN/A$18.7M$23.4M$21.4M
FY 2024$92.1M$-13.7M$-20.1MN/A$4.8M$13.4M$30.8M
FY 2023$71.5M$-26.4M$-17.6MN/A$-7.2MN/AN/A

Revenue grew from $71.5M in FY 2023 to $109.4M in FY 2025, and the company moved from operating losses to positive operating income of $11.7M in FY 2025. Per the market data section, operating margin is 10.7% and net margin is 4.7%. Per the RQD rating, ROIC is 7.3%, Altman Z is 2.68, and Piotroski F is 9/9. Debt fell from $30.8M to $21.4M over FY 2024 to FY 2025, and Debt/Equity is 0.17 per the RQD rating.

Recent Catalysts & News Wire Analysis

Per the recent news section, six items were published within roughly 15 hours of the data timestamp, all tagged YELLOW with impact label MARKET WIRE:

  • A Yahoo Finance item on a Trade Desk integration and programmatic capabilities, framed as a Q4 catalyst.
  • A StockInvest.us forecast piece asking whether OPRX is a buy.
  • A Stock Titan item noting that third-quarter results will precede a November 11 call.
  • A MarketScreener item on an integration of authenticated EHR and e-prescribing inventory with PulsePoint.
  • A Yahoo Finance UK seasonal returns chart.
  • A Stock Traders Daily item on volatility zones as tactical triggers.

Risk watch items: the Q3 results and the November 11 call are dated events whose content is not in the source data. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data, including SEC Form 4 insider, 13F institutional, and Congressional trade detail, is not available in source data. The RQD rating references institutional accumulation and insider cluster flow at the scoring level only.

Open Questions

  • What specific products and customers generate the $109.4M of FY 2025 revenue, and what drove the swing from operating losses to operating income?
  • What were the results of the third-quarter report referenced in the news wire, and how do they compare with the FY 2025 trend?
  • Which institutions and insiders account for the accumulation and cluster flow reflected in the RQD pillars?
  • What does the Trade Desk integration mean for revenue, and is it expected to contribute materially?
  • Why is EPS for each reported fiscal year listed as N/A, and how does that reconcile with the EPS (TTM) of 0.27?

OPRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OptimizeRx Corporation (OPRX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to OPRX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OPRX Bull vs. Bear Conversation Board β€” What's Your Call at $9.32?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OPRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OPRX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $11.06 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is OPRX (B- β€’ RQD 71/100) a Buy at $9.37?

Welcome to the OPRX (OptimizeRx Corporation) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy β€” Sound Institutional Accumulation) in Business Services. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (34.4x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.78 (-17.0%)
Spot @ $9.37

Pump the brakes on OPRX β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OPRX, but look at what you are paying: 34.4x trailing P/E with 67.3% gross margins. Unless OptimizeRx Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $10.78 (+15.0%)
Spot @ $9.37

OPRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OPRX, the market is fixating on short-term headline noise in Business Services and ignoring the balance sheet and cash flow trajectory. At $9.37 (52-wk range $4.54 - $21.09), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%